Novartis
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
Two Novartis drugs get first in class EU approvals
September 2, 2015Research and Development, Sales and Marketing Novartis
The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …
Novartis buys rights to GSK MS drug for up to $1 billion
August 21, 2015Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab
Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Bayer’s complaint over ‘misleading’ Novartis eye drug claims upheld
August 14, 2015Medical Communications Bayer, Eylea, Lucentis, Novartis, PMCPA, code of conduct
The industry’s code of conduct regulator has ruled in favour of Bayer in a dispute claims made by Novartis when …
CSL completes $275m Novartis vaccines acquisition
August 3, 2015Manufacturing and Production, Sales and Marketing CSL, Novartis, acquisitions, asset swap, vaccines
CSL Limited has finalised its transaction to acquire Novartis’s global influenza vaccine business for $275 million. The move means Novartis …
Novartis forms Mereo as UK biotech spin-off
July 29, 2015Research and Development Mereo, Novartis, biotech, rare diseases
Novartis has formed a new UK biotech company by selling three investigational drugs in exchange for shares in the new …
Novartis Foundation confirms Dr Joerg Reinhard as new chairman
July 27, 2015Manufacturing and Production, Medical Communications Dr Joerg Reinhardt, Novartis
The Novartis Foundation has confirmed several new members of its board of trustees, including a new chairman in Dr Joerg …
FDA approves Novartis drug Odomzo
July 27, 2015Sales and Marketing Novartis, Odomzo, basal cell carcinoma, skin cancer
The FDA has given the Swiss firm the go-ahead to market its drug for skin cancer. Odomzo (sonidegib, formerly LDE225) …
Sandoz and pharma division boost Novartis sales
July 21, 2015Sales and Marketing Alcon, Novartis, Sandoz, financial performance, financial results, income, profits, sales
Sales at Novartis reached $12.7 billion in the second quarter of 2015, while its operating income was $2.3 billion, the …
Novartis and Pfizer to close factories in India
July 21, 2015Manufacturing and Production India, Novartis, Pfizer, Sandoz, manufacturing
Two big pharma firms have announced they will close manufacturing facilities in India as they seek to restructures their global …
Novartis receives WHO nod for malaria drug Coartem
July 17, 2015Manufacturing and Production Coartem, Novartis, WHO, antimalarial, malaria, world health organization
The World Health Organization will add Novartis’ antimalarial treatment Coartem to the prequalified list of vaccines that is supplies to …
Novartis wins US nod for new heart drug
July 8, 2015Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril
The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
Novartis launches ViaOpta Apple Watch app
July 1, 2015Medical Communications Novartis, apple watch, apps, visual impairment, wearables
Novartis has launched new features of its ViaOpta app for use with the Apple Watch and other wearable devices. The …
Novartis spends $200m on pain firm Spinifex
June 29, 2015Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex
Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals. …
Latest content
FibroFind appoints Lee Borthwick as CEO
